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PolymorphismAbstract Background: Incidence of bladder cancer has increased rapidly worldwide in the past
few years. Environmental as well as genetic factors are involved in the etiology of bladder cancer.
Glutathione S transferase mu 1 (GSTM1) and glutathione S transferase theta 1 (GSTT1) genes are
two xenobiotic metabolizing genes in phase II of detoxification process.
Aim: The current study was aimed to find out the association of different environmental factors
and GSTM1 and GSTT1 gene polymorphisms with susceptibility to bladder cancer in Pakistani
population.
Method: Bladder cancer cases (236) and control blood samples (270) were screened using phenol
chloroform method of DNA extraction followed by multiplex PCR.
Results: With respect to age; bladder cancer was more prevalent in age >60 years and low grade
tumors were more frequent than high grade tumors. Smokers had a significantly higher incidence
rate of cancer; also family history of cancer was found to be strongly associated (P < 0.05) with
bladder cancer. Commonly reported symptoms by the patients of bladder cancer were hematuria,
lower urinary tract symptoms (LUTS) and flank pain. A larger number of patients had undergone
surgery, chemotherapy and radiotherapy. Similarly GSTM1 (OR 2.24; CI 1.5–3.2; P = 0.0001) and
GSTT1 (OR 2.9; CI 1.4–6.1; P = 0.002) gene deletion showed a highly significant association with
bladder cancer. Simultaneous deletions of both GSTM1 and GSTT1 genes also showed highly sig-
nificant association (OR 5.3; CI 2.1–13.1; P = 0.0001) with cancer risk. No association was found
when both of the two genes deletion was compared with bladder cancer among smokers.
Conclusion: This study suggests that GSTM1 and GSTT1 gene polymorphisms may be associ-
ated with increased susceptibility toward bladder cancer in Pakistani population.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).bladder
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The incidence rate of bladder cancer is higher in men as com-
pared to women and increases with age [1]. Smoking is the
major environmental factor involved in the development of
urinary bladder cancer. Cigarette smokers have four times
greater risk of onset of bladder cancer as compared to non-
smokers. More than 50% cases of bladder cancer have a his-
tory of smoking. In Pakistan smoking, fried items (fried
chicken, fried potatoes, samosay, pakoray, cutlets, cheese frit-
ters, roasted beef etc.) and sedentary life style up-regulated
bladder cancer development while consumption of fruits and
vegetables together with increased uptake of fluids down-
regulated urinary bladder carcinoma [2]. Regarding symptoms
of bladder cancer, about 85% patients have painless hematuria
as a major problem. Other commonly reported problems are
vesical irritability, frequency urgency and dysuria as well as
three p’s (PPP) i.e., Profuse, Periodic and Painless hematuria
[3]. Bladder cancer can be muscle invasive or noninvasive
and classified as high grade or low grade tumor respectively [4].
Bladder cancer development involves a complex interplay
of chemical, environmental and genetic factors. Different
metabolic enzymes have been encoded by glutathione S trans-
ferases super family and play an important role in the mecha-
nism of cellular detoxification. They catalyze different
reactions with bladder cancer carcinogens like amino biphe-
nyls and polycyclic aromatic hydrocarbons [5]. A number of
studies have been conducted to find out the association of
GSTs with bladder cancer. Both GSTM1 and GSTT1 genes
exhibit homozygous deletion polymorphisms which results in
null genotypes and the enzymatic activity is completely lost.
The frequency of null genotypes of these two genes is greater
in Asians as compared to Europeans. Positive association of
GSTM1 and GSTT1 deletion polymorphism and bladder car-
cinoma was found among Chinese, Indian, American and
Turkish populations [6–8]. GSTM1 and GSTT1 genes are also
risk factors for gastric, prostate, lung and head and neck can-
cer due to their hereditary loss and lack of enzymatic activity
[9–12]. However, data related to genetic status of GSTM1
and GSTT1 and their association to bladder cancer is not
available in Pakistani population. Therefore, current study is
designed to evaluate the association of GSTM1 and GSST1
gene polymorphisms with bladder cancer risk in Pakistani pop-
ulation. It also sheds light on the role of different environmen-
tal risk factors in the onset and development of bladder
carcinoma.
2. Subjects and methods
The work has been carried out in accordance with The Code of
the World Medical Association (Declaration of Helsinki) for
experiments in humans. After approval from institutional
ethics committee (Reference: IRB & EC # 308-157-2013) 270
controls and 236 urinary bladder cancer patients were selected
from Shifa International Hospital Islamabad (Urology depart-
ment) and National Oncology and Radiotherapy Institute
Islamabad (NORI) in the period of one year and 3 months.
Informed consent was signed from controls and patients.
Histopathologically confirmed bladder cancer patients by
oncologists were included in this study. Clinical anddemographic data were collected through a detailed question-
naire by interview. All patients and controls were of Pakistani
origin.
Blood was collected in 5 ml EDTA containing vacutainer
and stored in refrigerator at 4 C for DNA extraction. DNA
was isolated by phenol–chloroform extraction with the help
of different chemicals obtained from Merck, Germany.
Screening of GSTM1 and GSTT1 was done by multiplex
PCR (UNIEQUIP Cat# CMG96G; Germany). Following




GACTTC-30. CYPIAI were used as internal control gene.
Master Mix was prepared using dNTPs, magnesium chloride,
buffer, Taq polymerase and PCR water obtained from Solis
biodyne. PCR was performed at 95 C for 5 min followed by
30 cycles at 94 C for 45 s, annealing temperature of 59 C
for 45 s, 72 C for 1 min and final extension was done at
72 C for 10 min. Then, electrophoresis was performed by
running all PCR products on 2% agarose gel and bands were
visualized under UV light in gel documentation system
(Wealtec Dolphin-DOC plus Cat#1141004 USA). Product size
for GSTM1 and GSTT1 was 270 bp and 215 bp respectively
obtained by comparing with the DNA ladder [13].
The genotypic distribution of GSTM1 and GSTT1 genes
were analyzed by chi square test among control and bladder
cancer patients. The association of genetic polymorphisms,
bladder cancer, age, sex, smoking, residential area and family
history of cancer was estimated from logistic regression analy-
sis using odds ratio (OR) with 95% confidence interval (CI).
Statistical analysis was performed using SPSS 17.0 version
and significance level was observed at P < 0.05 (see Fig. 1).3. Results
The mean age of bladder cancer patients and controls was 59.5
(±15.76) years and 56.5(±15.67) years respectively. More
than 60% were >60 years of age. Different demographic fea-
tures were presented in Table 1. It was found that smoking was
highly significantly associated (cigarette P = 0.03 and huqqa
P = 0.002) with bladder cancer risk among Pakistani popula-
tion. Residential area (open or congested) of bladder cancer
patients showed non-significant association with bladder can-
cer. A major finding in this study group was that family history
of cancer played a major role in the onset of bladder cancer. It
was found to be significantly (P = 0.001) associated with the
incidence of bladder cancer. All the patients were having histo-
logical type transitional cell carcinoma (TCC) showing that it
is very common. We observed that hematuria (94.8%), lower
urinary tract symptoms (LUTS) (72.4%) and flank pain
(67.2%) are major symptoms of urinary bladder cancer. LUTS
refers to a group of symptoms including storage or irritative
symptoms (increased frequency and urgency of urination,
painful urination and excessive urination at night) and voiding
or obstructive symptoms (poor stream, hesitancy, terminal
dribbling, incomplete voiding and overflow incontinence).
Low grade tumors (58%) and non-invasive muscle bladder
cancer (55%) were more frequent among patients. Most of
the bladder cancer patients (68%) had undergone surgery. A
Figure 1 2% agarose gel showing GSTM1 and GSTT1 bands and null genotypes in controls (N) and bladder cancer patients (CaP).
CYP1A1 is used as an internal control.
Table 1 Demographic features of normal healthy controls and bladder cancer (BC) patients.
Parameters Control group (%) n BC patients (%) n OR (95% CI) Chi square P value
Age (years)






Women (17.03) 46 (17.34) 41 0.9 (0.6–1.5) 0.01 0.9
Men (82.96) 224 (82.65) 195
Residential area
Open (84.4) 228 (86.8) 205 0.87 (0.4–1.3) 0.59 0.43
Congested (15.5) 42 (13.13) 31
Smoking
Cigarette Yes (14.4) 39 (51.6) 122 5.0 (3.3–7.6) 80.5 0.03
No (85.5) 231 (48.3) 114
Huqqa Yes (0.7) 2 (5.08) 12 7.7 (1.5–32.4) 8.83 0.002
No (99.2) 268 (94.9) 224
Cigarettes per day
<15 (23.0) 9 (36.8) 45 0.5 (0.2–1.1) 2.52 0.11
>15 (76.9) 30 (63.1) 77
Mean years
Smoking 24.5 15.6 – – –
Naswar chewing 0 1 – 1.9 0.15
Family history of cancer 0 (10.5) 25 – 27.1 0.001
Significant factors are italicized.
Huqqa is a kind of smoking.
Useful determinants for bladder cancer 43large number of bladder cancer patients were at chemotherapy
(87%) and radiotherapy (73%). It showed that one kind of
treatment is not enough to cure the disease.GSTM1 (OR 2.24; CI 1.5–3.2; P = 0.0001) and GSTT1
(OR 2.9; CI 1.4–6.1; P = 0.002) gene deletions were strongly
associated with the increased risk of bladder cancer as
Table 2 GSTM1 and GSTT1 genotype distributions among controls and bladder cancer patients.
Genotypes BC patients (n) 236 Control (n) 270 OR (95% CI) P value
GSTM1
Present 131 (55.5) 199 (73.7)
Null 105 (44.5) 71 (26.3) 2.24 (1.5–3.2) 0.0001
GSTT1
Present 226 (95.8) 239 (88.5)
Null 10 (4.2) 31 (11.5) 2.9 (1.4–6.1) 0.002
Both GSTM1 & GSTT1
Present 230 (97.5) 239 (88.5)
Null 6 (2.5) 31 (11.5) 5.3 (2.1–13.1) 0.0001
GSTM1 and smoking
Smokers in study 122 (51.7) 39 (14.4) 0.8 (0.4–1.7) 0.63
Present 51 (41.8) 18 (46.2)
Null 71 (5) 21 (53.8)
GSTT1 and smoking
Smokers in study 122 (51.7) 39 (14.4) 0.6 (0.1–3.2) 0.62
Present 113 (92.6) 37 (94.9)
Null 9 (7.4) 2 (5.1)
n= number of controls and bladder cancer patients.
BC = bladder cancer.
Significant factors are italicized.
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genes was also associated (OR 5.3; CI 2.1–13.1; P = 0.0001)
with greater risk toward bladder cancer. GSTM1 (P = 0.63)
and GSTT1 (P = 0.62) gene deletions and smoking were
found not to be associated with bladder cancer risk in
Pakistani population. However, percentage of gene deletions
among smokers was greater than non-smokers but we are
unable to find any significance.
4. Discussion
In this study mean age of patients was 59.5(±15.76) years and
approximately 60% of patients were above the age of 60 years.
Approximately 90% of bladder cancer cases were of transi-
tional cell carcinoma (TCC). Similar results were observed in
different studies [8,14–15].
Cigarette smoking is an important factor in the develop-
ment of bladder cancer. In this study, cigarette and huqqa
smoking (P = 0.03 and P = 0.002) proved to be a significant
risk factor for bladder cancer. These results were also pre-
sented in a number of studies among Indian, Chinese, Turkish
and Serbian populations (6, 8, 14 and 16]. It was noted that
occurrence of low grade tumors was a little higher than high
grade tumors and similar results were observed for muscle
invasive and non-invasive tumor stages similar to the studies
in Turkish, Korean and Iranian populations [7,8–15].
GSTM1 and GSTT1 gene polymorphisms have been associ-
ated with a wide variety of cancers including bladder cancer
[16]. In our study it was found that GSTM1 null polymor-
phism was associated (P = 0.0001) with risk of bladder cancer.
Similar results have been reported in other studies that
GSTM1 deletion was a risk factor for the development of blad-
der cancer [17,18]. Two different review papers also depicted
association between GSTM1 null deletion and bladder cancer
risk [19,20]. We tried to find the association between smoking,
GSTM1 null deletion and bladder cancer risk however, no sig-nificant association was found. Similar results had been shown
by an Iranian, an Indian and two German studies that GSTM1
deletion does not show any association with smoking and
bladder cancer [8,21–23]. We also investigated the association
of GSTT1 and bladder cancer. It was found that GSTT1 was
strongly associated (P = 0.002) with urinary bladder cancer.
Our results were similar to a number of other studies
previously conducted in Turkey, India, Brazil and Korea
[8,23–26]. It was found that role of GSTT1 gene deletions in
bladder cancer was not dependent on smoking status as among
Indians, Germans, Iranians and Spanish populations
[8,18,21–23]. Both genes GSTM1 and GSTT1 have been eval-
uated in combination with each other. It was depicted that
dual null deletion of GSTM1 and GSTT1 genes was also asso-
ciated with increased susceptibility to bladder cancer.5. Conclusion
It was concluded that smoking was an important risk factor
for urinary bladder carcinoma. GSTM1, GSTT1 and combina-
tion of the two gene polymorphisms were strongly associated
with bladder cancer risk in Pakistani population. No associa-
tion was found between genetic deletions of GSTM1 and
GSTT1 and bladder carcinoma among smokers.Ethical approval
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